Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis : Pooled Analysis of Four Phase 3 Trials
Adsit, Sandra (TCR Medical Corporation, San Diego, USA)
Zaldivar, Enrique Rivas (Dermos, Guatemala)
Sofen, Howard (UCLA School of Medicine, Los Angeles, USA)
Dei-Cas, Ignacio (Halitus, Buenos Aires, Argentina)
Maldonado-García, César (Centro Dermatológico "Dr. Ladislao de la Pascua", Mexico)
Peñaranda, Elkin O. (Riesgo de Fractura S.A., Bogota, Colombia)
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau)
Meng, Xiangyi (Novartis Pharmaceuticals Corporation, East Hanover, USA)
Fox, Todd (Novartis Pharma AG, Basel, Switzerland)
Guana, Adriana (Novartis Pharmaceuticals Corporation, East Hanover, USA)
Universitat Autònoma de Barcelona

Data:	2017
Resum:	There is little evidence available on the efficacy and safety of biologic therapies for the treatment of psoriasis in Hispanic patients. Secukinumab is demonstrated to be highly effective for clearing psoriasis. The aim of this study was to compare the efficacy and safety of secukinumab in Hispanic and non-Hispanic patients. Data were pooled from four phase 3 studies of secukinumab in patients with moderate-to-severe plaque psoriasis. Patients who self-identified as Hispanic were included in the Hispanic subgroup. Efficacy responses (Psoriasis Area and Severity Index [PASI] 75/90/100 and Investigator's Global Assessment 2011 modified version 0/1) for secukinumab 300 mg were greater than for etanercept at week 12 in the Hispanic and non-Hispanic patient subgroups. At week 12 with secukinumab 300 mg, PASI 90/100 responses were achieved by 70. 6%/35. 9% of Hispanic patients and 58. 0%/28. 1% of non-Hispanic patients. At week 12 with secukinumab 150 mg, PASI 90/100 responses were achieved by 59. 5%/25. 1% of Hispanic patients and 41. 2%/13. 4% of non-Hispanic patients. In both subgroups, peak efficacy responses with secukinumab were observed at week 16 and were maintained to week 52. Secukinumab is highly effective for clearing psoriasis in both Hispanic and non-Hispanic patients. Novartis Pharmaceutical Corporation. The online version of this article (doi:10. 1007/s12325-017-0521-z) contains supplementary material, which is available to authorized users.
Nota:	Altres ajuts: This study was funded by Novartis Pharmaceutical Corporation. Article processing charges and the fee for open access were funded by Novartis Pharmaceutical Corporation. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. Technical assistance with editing and styling of the manuscript for submission was provided by Scott Forbes, Ph.D., of Oxford PharmaGenesis Inc. and was funded by Novartis Pharmaceuticals Corporation.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Biologic therapy ; Dermatology Life Quality Index ; Hispanic ; IL-17 ; Moderate-to-severe psoriasis ; Non-Hispanic ; Pooled analysis ; Psoriasis Area and Severity Index ; Secukinumab ; Subcutaneous injection
Publicat a:	Advances in Therapy, Vol. 34 (april 2017) , p. 1327-1339, ISSN 1865-8652

DOI: 10.1007/s12325-017-0521-z
PMID: 28397079

13 p, 1.5 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats